Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(3):472-479 | DOI: 10.5507/bp.2014.015
Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic
- a Department of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- b Department of Occupational Medicine, General University Hospital in Prague and 1st Faculty of Medicine, Charles University in Prague
- c Department of Occupational Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc
Aims: Pleural mesothelioma is a highly aggressive and difficult-to-treat form of cancer induced by asbestos in 80-90% of cases. The population group most at risk of the condition are asbestos-exposed workers. Mesothelin or soluble mesothelin-related protein (SMRP) is studied as a potential marker of mesothelioma in the at-risk population.
Methods: The study comprised 239 subjects with a mean duration of occupational exposure to asbestos of 19.9 years. In all of them, a complete medical history was taken, focused on exposure duration and a physical examination, a chest X-ray or other imaging investigations and a lung function test were performed. Their serum SMRP levels were measured and biopsy samples were taken to diagnose pleural disease. Based on the above examinations, the subjects were classified into subgroups and serum SMRP concentrations were statistically analyzed with respect to individual parameters.
Results: In asbestos-exposed individuals, mesothelin levels were significantly higher in those with pathological X-ray findings than in those with normal X-ray results (0.78 ± 0.63 vs. 0.50 ± 0.35, P<0.0001). The group of patients with benign disease had statistically significantly higher mesothelin levels than those with normal X-ray findings (0.755 ± 0.543 vs. 0.50 ± 0.35, P<0.001). In the group with present malignant processes, mesothelin levels were higher than in individuals with benign disease (1.19 ± 0.89 vs. 0.76 ± 0.54, P=0.015). Only a weak correlation was found between mesothelin levels and asbestos exposure duration. There were relatively high sensitivity and high specificity (75% and 90.6%, respectively) of serum mesothelin for pleural mesothelioma. However, given the small number of mesothelioma cases in the group, the results cannot be considered as statistically significant.
Conclusions: In persons followed up for asbestos exposure, increased mesothelin levels signalize pathological processes in the chest and correlate with severity of the disease. The study suggests that mesothelin cannot be considered a reliable marker for the early stage of malignant degeneration of pleural disease but only an additional criterion for examination of the followed-up individuals.
Keywords: mesothelin, asbestos-exposed population, malignant pleural mesothelioma
Received: November 18, 2013; Accepted: March 21, 2014; Prepublished online: April 29, 2014; Published: September 30, 2015 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, Chan CC, Wen CP, Furuya S, Higashi T, Chien LC, Ohtaki M. Ecological association between asbestos-related diseases and historici asbestos consumption: an international analysis. Lancet 2007;369:844-9.
Go to original source...
Go to PubMed...
- Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
Go to original source...
Go to PubMed...
- Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Péchoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W, European Respiratory Society/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479-95.
Go to original source...
Go to PubMed...
- Palatka K, Kolek V, Tichý T, Musilová K. Zku¹enosti s diagnostikou a léèbou maligního mezoteliomu, srovnání období 1990-1999 a 2000-2004. Stud Pneumol Phthiseol 2007;67:188-93.
- Pelclová D, Fenclová Z, Urban P. Asbestos exposure, legislation and diseases in the Czech Republic. Cent Eur J Public Health 2007;15(3):99-102.
Go to original source...
- Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions. Ann Thorac Surg 2008;85:265-72.
Go to original source...
Go to PubMed...
- Pass HI, Carbone M. Current Status of Screening for Malignant Pleural Mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:97-104.
Go to original source...
Go to PubMed...
- Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a kohort of workers formerly exposed to asbestos. Arch Toxicol 2011;85:185-92.
Go to original source...
Go to PubMed...
- Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
Go to original source...
Go to PubMed...
- Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-93.
Go to original source...
Go to PubMed...
- Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-71.
Go to original source...
Go to PubMed...
- Bourdes V, Boffetta P, Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur J Epidemiol 2000;16:411-7.
Go to original source...
Go to PubMed...
- Maule MM, Magnani C, Dalmasso P, Mirabelli D, Merletti F, Biggeri A. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect 2007;115:1066-71.
Go to original source...
Go to PubMed...
- Stahel RA. Malignant pleural mesothelioma: A new standard of care. Lung Cancer 2006;54(S2):S9-S14.
Go to original source...
Go to PubMed...
- Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718-21.
- Ohar J, Sterling DA, Bleecker E, Donohue J. Changing patterns in asbestos-induced lung dinase. Chest 2004;125(2):744-53.
Go to original source...
Go to PubMed...
- Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante P, Gennaro V, Gorini G, Menegozzo M, Mensi C, Merler E, Mirabelli D, Montanaro F, Musti M, Pannelli F, Romanelli A, Scarselli A, Tumino R. Italian Mesothelioma Register (ReNaM) Working Group. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007;43(18):2722-8.
Go to original source...
Go to PubMed...
- Roberts HC, Patsios DA, Paul NS, DePerrot M, Teel W, Bayanati H, Shepherd F, Johnston MR. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 2009;4:620-8.
Go to original source...
Go to PubMed...
- West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med 2006;27:335-54.
Go to original source...
Go to PubMed...
- Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-6.
Go to original source...
Go to PubMed...
- Hyland RA, Ware S, Johnson AR, Yates DH. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007;33:286-92.
Go to original source...
Go to PubMed...
- O'Byrne KJ, Edwards JG, Waller DA. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 2004;45(S1):S45-S48.
Go to original source...
Go to PubMed...
- Neumann V, Löseke S, Nowak D, Herth FJF, Tannapfel A. Malignant Pleural Mesothelioma. Incidence, Etiology, Diagnosis, Treatment, and Occupational Health. Dtsch Arztebl Int 2013;110(18):319-26.
Go to original source...
Go to PubMed...
- Kao SC, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, van Zandwijk N, Clarke S. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer 2013;14(1):70-7. doi: 10.1016/j.cllc.2012.03.011
Go to original source...
Go to PubMed...
- Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass HI, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP. IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012;7(11):631-9.
Go to original source...
Go to PubMed...
- Kolek V, Zatloukal P, Pe¹ek M, Salajka F, Marel M, Roubec J, Skøièková J, Sixtová D, Petru¾elka L, Grygárková I, Koubková L, ©tícha M. Pemetrexed in the first line chemotherapy of malignant pleural mesothelioma. A multicentre prospective study. 14th World Conference on Lung Cancer. Journal of Thoracic Oncology 2011;6(6):1360-1.
- Kolek V, Pe¹ek M, Zatloukal P, Salajka F. Pemetrexed in the first line chemotherapy of malignant pleural mesothelioma. the Czech prospective study. 24th International congress on anti-cancer treatment. A World leading educational congress. Abstract book, Paris, France 5-7 February 2013.(IC/AB967),p.314-5.
- Antman K, Pass H, Sciff P. Benign and malignant mesothelioma. In: deVita, VT, Jr., Hellman, S, Rosenberg, S, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott-Raven, 2001, p.1943-70.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
Go to original source...
Go to PubMed...
- Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer. J Thorac Oncol 2008;3:1317-24.
Go to original source...
Go to PubMed...
- Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble Mesothelin Related Protein in Mesothelioma. J Thorac Oncol 2006;1:172-4
Go to original source...
Go to PubMed...
- Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium. Cancer Res 1992;52:181-6.
Go to PubMed...
- Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers. Pathology International 2006;56(11):649-54.
Go to original source...
Go to PubMed...
- Rump A, Morikawa I, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8.
Go to original source...
Go to PubMed...
- Hassan R, Remaley AT, Samson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer. Clin Cancer Research 2006;12:447-53.
Go to original source...
Go to PubMed...
- Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case-control study. Lung Cancer 2008;61:235-43.
Go to original source...
Go to PubMed...
- Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P. Soluble Mesothelin-related Peptides in the Diagnosis of Malignant Pleural Mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
Go to original source...
Go to PubMed...
- Ordonez,NG. Immunohistochemical diagnosis of epithelioid mesothelioma. An update. Arch Pathol Lab Med 2005;129:1407-14.
Go to original source...
- Watanabe H, Okada G, Ohtsubo K, Yamaguchi Y, Mouri H, Motoo Y, Wakabayashi T, Sawabu N. Expression of mesothelin mRNA in pure pancreatic juice from patiens with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pankreas, and chronic pankreatitis. Pancreas 2005;30(4):349-54.
Go to original source...
Go to PubMed...
- Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. Mesothelin expression in human lung cancer. Clin Cancer Rev 2007;13(5):1571-5.
Go to original source...
Go to PubMed...
- Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, Kussick SJ, Gown AM. Evaluation of 12 antibodies for distinguishing between epithelioid mesothelioma from adenocarcinoma: Identification of a free-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006;19:514-23.
Go to original source...
Go to PubMed...
- Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y, Hino O. Novel ELISA systém for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 2006;97:928-32.
Go to original source...
Go to PubMed...
- Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellström KE, Hellström I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96:11531-6.
Go to original source...
Go to PubMed...
- Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovaria nand pancreatic cancer. BMC Cancer 2004;4:19-29.
Go to original source...
Go to PubMed...
- Hassan R, Bera TK, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Rev 2004;10:8751-3.
Go to original source...
Go to PubMed...
- Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE. Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker. Cancer Epidemiology, Biomarkers Prev 2006;15:1014-20.
Go to original source...
- Ho M, Onda M, Wang Q, Hassan R, Pastan I, Lively MO. Mesothelin Is Shed from Tumor Cells. Cancer Epidemiology, Biomarkers Prev 2006;15:1751.
Go to original source...
- Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C, Scherpereel A, Dabouis G, Grégoire M. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Science 2008;99:590-4.
Go to original source...
Go to PubMed...
- Felten MK, Khatab K, Knoll L, Schettgen T, Müller-Berndorff H, Kraus T. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Int Arch Occup Environ Health 2014;87(2): 195-204. doi 10.1007/s00420-013-0853-1
Go to original source...
Go to PubMed...
- Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 2010;48:869-74.
Go to original source...
Go to PubMed...
- Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpré P, De Vuyst P, Bosquée L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 2012;141:477-84.
Go to original source...
Go to PubMed...
- Filiberti R, Marroni P, Mencoboni M, Mortara V, Caruso P, Cioè A, Michelazzi L, Merlo DF, Bruzzone A, Bobbio B, Del Corso L, Galli R, Taveggia P, Dini G, Spigno F. Individual predictors of increased serum mesothelin in asbestos-exposed workers. Med Oncol 2013;30:422. doi 10.1007/s12032-012-0422-6
Go to original source...
Go to PubMed...
- Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
Go to original source...
Go to PubMed...
- Marini V, Michelazzi L, Cioé A, Fucile C, Spigno F, Robbiano L. Exposure to asbestos: Correlation between blood levels of mesothelin and frequency of micronuclei in peripheral blood lymphocytes. Mutat Res 2011;721(1):114-7.
Go to original source...
Go to PubMed...
- Portal JAR, Becerra ER, Rodríguez D, Michavila IA, Martínez AQ, Roza CD, Jiménez AL, Montes II, Rivas PC. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009;18:646-50.
Go to original source...
Go to PubMed...
- Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW. Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma. Cancer Epidemiol Biomarkers Prev 2010;19(9):2238-46.
Go to original source...
Go to PubMed...
- Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma. Am J Respir Crit Care Med 2010;181:620-5.
Go to original source...
Go to PubMed...
- Fujimoto N, Gemba K, Asano M, Wada S, Ono K, Ozaki S, Kishimoto T. Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma. Experimental Therapeutic Med 2010;1:313-7.
Go to original source...
- Amati M, Tomasetti M, Mariotti L, Tarquini LM, Valentino M, Santarell, L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res 2008;655:52-8.
Go to original source...
Go to PubMed...
- Foddis R, Vivaldi A, Filiberti R, Puntoni R, Mutti L, Ambrosino N, Chella A, Guglielmi G, Gattini V, Buselli R, Perretta S, Cristaudo A. Serum mesothelin dosages in follow-up of previously exposed workers. Ital Med Lav Ergon 2007;29(3):342-5.
- Park EK, Sandrini A., Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR. Soluble Mesothelin-Related Protein in an Asbestos- Exposed Population. The Dust Diseases Board Cohort Study. Am J Respir Crit Care Med 2008;78:832-7.
Go to original source...
Go to PubMed...
- Mencoboni M, Michelazzi LA, Cioé A, Bruzzone A, Delcorso L, Mortara V, Marroni P, Dini G, Marcenaro S, Spigno F. Mesothelin and individual characteristics in a cohort of asbestos exposed workers. Abstract no.2412, ESMO 2012
Go to original source...
- Grigoriu B, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P. Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment. Clin Cancer Res 2007;13(10):2928-35.
Go to original source...
Go to PubMed...
- Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment. Am J Respir Crit Care Med 2009;179:950-4.
Go to original source...
Go to PubMed...
- Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW. Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma. J Thorac Oncol 2008;3(8):851-7.
Go to original source...
Go to PubMed...
- Creaney J, Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW. Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma. Chest 2007;132:1239-46.
Go to original source...
Go to PubMed...
- Park EK, Yates DH, Creaney J, Thomas PS, Robinson BW, Johnson AR, Association of Biomarker Levels with Severity of Asbestos-Related Diseases. Safety and Health at Work 2012;3(1):17-21. doi: 10.5491/SHAW.2012.3.1.17
Go to original source...
Go to PubMed...
- Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin-related protein - A blood test for mesothelioma. Lung Cancer 2005;49(Suppl 1):109-11.
Go to original source...
Go to PubMed...
- Creaney J, Robinson BW. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 2009;15(4):366-70.
Go to original source...
Go to PubMed...
- Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY. MESOMARKTM: A Potential Test for Malignant Pleural Mesothelioma. Clinical Chemistry 2007;53:666-72.
Go to original source...
Go to PubMed...
- Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R. Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer. Clin Cancer Res 2007;13:5076-81.
Go to original source...
Go to PubMed...
- Di Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, Mera E, Bisceglia L, Molinini R. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007;45:634-8.
Go to original source...
Go to PubMed...
- Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-analysis. Respir Med 2010;104(1):149-56.
Go to original source...
Go to PubMed...
- Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541-9.
Go to original source...
Go to PubMed...
- Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC. Clinical Impact and Reliability of Pleural Fluid Mesothelin in Undiagnosed Pleural Effusions. Am J Respir Crit Care Med 2009;180:437-44.
Go to original source...
Go to PubMed...
- Grigoriu BD, Grigoriu C, Chahine B,Gey T, Scherpereel A. Clinical utility of diagnostic markers for malignant pleuraå mesothelioma. Monaldi Arch Chest Dis 2009;71:31-8.
Go to original source...
Go to PubMed...
- Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008;14:303-9.
Go to original source...
Go to PubMed...
- Jakubec P, Grygárková I, Kolek V, Cwiertka K, Kapustová M. Mezotelin v detekci mezoteliomu pleury v diagnostice pohrudnièního výpotku. Studia pneumol phthiseol 2010;70(6):243-8.
- Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28(20):3316-22.
Go to original source...
Go to PubMed...
- Pelclova D, Fenclova Z, Urban P. Occupational cancer in the Czech Republic - a tip of the iceberg? Eur J Oncol 2011;16:149-61.